After decades of research, nanotechnology has been used in a broad array of biomedical products including medical devices, drug products, drug substances, and pharmaceutical-grade excipients. But like many great achievements in science, there is a fine balance between the risks and opportunities of this new technology. Some materials and surface structures in the nanosize range can exert unexpected toxicities and merit a more detailed safety assessment. Regulatory agencies such as the United States Food and Drug Administration or the European Medicines Agency have started dealing with the potential risks posed by nanomaterials. Considering that a thorough characterization is one of the key aspects of controlling such risks this review presents the regulatory background of nanosafety assessment and provides some practical advice on how to characterize nanomaterials and drug formulations. Further, the challenges of how to maintain and monitor pharmaceutical quality through a highly complex production processes will be discussed.
MARQUES Margareth;
CHOO Qiuyi;
ASHTIKAR Mukul;
ROCHA Thais Correa;
BREMER Susanne;
WACKER Matthias;
Marques, M., Choo, Q., Ashtikar, M., Rocha, T., Bremer, S. and Wacker, M., Nanomaterials - Tiny particles and big challenges, ADVANCED DRUG DELIVERY REVIEWS, ISSN 0169-409X, 151-152, 2019, p. 23-43, JRC117055.
2019-12-12
ELSEVIER SCIENCE BV
JRC117055
0169-409X (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC117055,
10.1016/j.addr.2019.06.003 (online),
